Table 4.
No. of patients (%) | ADA negative (n = 103) | ADA positive (n = 28) |
---|---|---|
Lack of efficacy | 1 (1.0) | 1 (3.6) |
Permanent treatment discontinuation due to lack of efficacy | 1 (1.0) | 1 (3.6) |
Loss of efficacy | 0 | 0 |
ADA antidrug antibody
No. of patients (%) | ADA negative (n = 103) | ADA positive (n = 28) |
---|---|---|
Lack of efficacy | 1 (1.0) | 1 (3.6) |
Permanent treatment discontinuation due to lack of efficacy | 1 (1.0) | 1 (3.6) |
Loss of efficacy | 0 | 0 |
ADA antidrug antibody